Evolutionary dynamics of imatinib-treated leukemic cells by stochastic approach

• Autorzy: Nicola Pizzolato , Davide Valenti , Dominique Adorno , Bernardo Spagnolo
• Języki publikacji: EN

Abstrakty

EN

The evolutionary dynamics of a system of cancerous cells in a model of chronic myeloid leukemia (CML) is investigated by a statistical approach. Cancer progression is explored by applying a Monte Carlo method to simulate the stochastic behavior of cell reproduction and death in a population of blood cells which can experience genetic mutations. In CML front line therapy is represented by the tyrosine kinase inhibitor imatinib which strongly affects the reproduction of leukemic cells only. In this work, we analyze the effects of a targeted therapy on the evolutionary dynamics of normal, first-mutant and cancerous cell populations. Several scenarios of the evolutionary dynamics of imatinib-treated leukemic cells are described as a consequence of the efficacy of the different modelled therapies. We show how the patient response to the therapy changes when a high value of the mutation rate from healthy to cancerous cells is present. Our results are in agreement with clinical observations. Unfortunately, development of resistance to imatinib is observed in a fraction of patients, whose blood cells are characterized by an increasing number of genetic alterations. We find that the occurrence of resistance to the therapy can be related to a progressive increase of deleterious mutations.

Słowa kluczowe

EN

stochastic dynamics; cancer evolution; complex systems

• Czasopismo: Open Physics
• Rocznik: 2009
• Tom: 7
• Numer: 3
• Strony: 541-548

Daty

wydano

2009-09-01

online

2009-06-25

Twórcy

autor

Nicola Pizzolato,

autor

Davide Valenti,

autor

Dominique Adorno

• Dipartimento di Fisica e Tecnologie Relative, Università di Palermo and CNISM-INFM, Viale delle Scienze, edificio 18, I-90128, Palermo, Italy

autor

Bernardo Spagnolo

Bibliografia

• [1] F. Michor, M. Nowak, S.A. Franketal, P. Roy. Soc. Lond. B Bio. 270, 2017 (2003) http://dx.doi.org/10.1098/rspb.2003.2483[Crossref]
• [2] F. Michor, Y. Iwasa, M. A. Nowak, Nat. Rev. Cancer 4, 197 (2004) http://dx.doi.org/10.1038/nrc1295[Crossref]
• [3] Y. Iwasa, F. Michor, M. Nowak, Genetics 166, 1571 (2004) http://dx.doi.org/10.1534/genetics.166.3.1571[Crossref]
• [4] F. Michoretal, Nature 435, 1267 (2005) http://dx.doi.org/10.1038/nature03669[Crossref]
• [5] L. H. Abbott, F. Michor, Brit. J. Cancer 95, 1136 (2006) http://dx.doi.org/10.1038/sj.bjc.6603310[Crossref]
• [6] Y. Brumer, F. Michor, E. I. Shakhnovich, J. Theor. Biol. 241, 216 (2006) http://dx.doi.org/10.1016/j.jtbi.2005.11.018[Crossref]
• [7] D. Dingli, F. Michor, Stem Cells 24, 2603 (2006) http://dx.doi.org/10.1634/stemcells.2006-0136[Crossref]
• [8] A. Fiasconaro, B. Spagnolo, A. Ochab-Marcinek, E. Gudowska-Nowak, Phys. Rev. E 74, 041904 (2006)
• [9] A. L. Garneretal, Cell Proliferat. 39, 15 (2006) http://dx.doi.org/10.1111/j.1365-2184.2006.00368.x[Crossref]
• [10] B. N. Kholodenko, Nat. Rev. Mol. Cell Bio. 7, 165 (2006) http://dx.doi.org/10.1038/nrm1838[Crossref]
• [11] N. L. Komarova, B. Math. Biol. 68, 1573 (2006) http://dx.doi.org/10.1007/s11538-005-9046-8[Crossref]
• [12] F. Michor, M. Nowak, Y. Iwasa, Curr. Pharm. Design 12, 261 (2006) http://dx.doi.org/10.2174/138161206775201956[Crossref]
• [13] F. Michor, Y. Iwasa, J. Theor. Biol. 241, 676 (2006) http://dx.doi.org/10.1016/j.jtbi.2006.01.006[Crossref]
• [14] F. Michor, Y. Iwasa, M. Nowak, P. Natl. Acad. Sci. USA 103, 14931 (2006) http://dx.doi.org/10.1073/pnas.0607006103[Crossref]
• [15] I. Roederetal, Nat. Med. 12, 1181 (2006) http://dx.doi.org/10.1038/nm1487[Crossref]
• [16] N. L. Komarova, D. Wodarz, Theor. Popul. Bio. 72, 523 (2007) http://dx.doi.org/10.1016/j.tpb.2007.08.003[Crossref]
• [17] H. H. Changetal, Nature 453, 544 (2008) http://dx.doi.org/10.1038/nature06965[Crossref]
• [18] A. Fiasconaro, A. Ochab-Marcinek, B. Spagnolo, E. Gudowska-Nowak, Eur. Phys. J. B 65, 435 (2008) http://dx.doi.org/10.1140/epjb/e2008-00246-2[Crossref]
• [19] V. P. Zhdanov, Eur. Biophys. J. 37, 1329 (2008) http://dx.doi.org/10.1007/s00249-008-0341-9[Crossref]
• [20] C. L. Sawyers, New Engl. J. Med. 340, 1330 (1999) http://dx.doi.org/10.1056/NEJM199904293401706[Crossref]
• [21] P. Nowell, D. Hungerford, Science 132, 1497 (1960)
• [22] E. Shtivemman, B. Lifshitz, R. P. Gale, E. Canaani, Nature 315, 550 (1985) http://dx.doi.org/10.1038/315550a0[Crossref]
• [23] A. E. Andaloussi, C. Bilhou-Nabera, J. Biomed. Biotechnol., 92385 (2007)
• [24] P. McGlave, Leukemia 6, 115 (1992) [PubMed]
• [25] R. A. Cliftetal, Blood 84, 4368 (1994)
• [26] D. G. Savageetal, Brit. J. Haematol. 99, 30 (1997) http://dx.doi.org/10.1046/j.1365-2141.1997.3453159.x[Crossref]
• [27] B. J. Drukeretal, Nat. Med. 2, 561 (1996) http://dx.doi.org/10.1038/nm0596-561[Crossref]
• [28] R. Hehlmann, A. Hochhaus, U. Berger, A. Reiter, Ann. Hematol. 79, 345 (2000) http://dx.doi.org/10.1007/s002770000167[Crossref]
• [29] M. Talpazetal, Blood 99, 1928 (2002) http://dx.doi.org/10.1182/blood.V99.6.1928[Crossref]
• [30] J. Cortesetal, Clin. Carcer Res. 11, 3425 (2005) http://dx.doi.org/10.1158/1078-0432.CCR-04-2139[Crossref]
• [31] A. Hochhaus, Ann. Oncol. 17, 274 (2006) http://dx.doi.org/10.1093/annonc/mdl273[Crossref]
• [32] E. Weisberg, J. D. Griffin, Drug Resist. Update. 4, 22 (2001) http://dx.doi.org/10.1054/drup.2001.0180[Crossref]
• [33] E. Weisberg, J. D. Griffin, Drug Resist. Update. 6, 231 (2003) http://dx.doi.org/10.1016/S1368-7646(03)00062-1[Crossref]
• [34] F. Michor, Stem Cells 25, 1114 (2007) http://dx.doi.org/10.1634/stemcells.2006-0638[Crossref]
• [35] J. J. Berman, G. W. Moore, Anal. Cell. Pathol. 4, 359 (1992) [PubMed]
• [36] P. P. Delsanto, A. Romano, M. Scalerendi, G. P. Pescarmona, Phys. Rev. E 62, 2547(2000) http://dx.doi.org/10.1103/PhysRevE.62.2547[Crossref]
• [37] A. M. Klein, D. P. Doupé, P. H. Jones, B. D. Simons, Phys. Rev. E 76, 021910(2007)
• [38] C. Lengauer, K. W. Kinzler, B. Vogelstein, Nature 396, 643 (1998) http://dx.doi.org/10.1038/25292[Crossref]
• [39] J. C. Claussen, A. Traulsen, Phys. Rev. E 71, 25101(R), (2005)
• [40] S. H. Moolgavkar, A. G. Knudson, J. Natl. Cancer I. 66, 1037 (1981)
• [41] A. G. Knudson, Nat. Rev. Cancer 1, 157 (2001) http://dx.doi.org/10.1038/35101031[Crossref]
• [42] S. A. Frank, Y. Iwasa, M. Nowak, Genetics 163, 1527 (2003)
• [43] P. A. P. Moran, The Statistical Processes of Evolutionary Theory (ClarendonPress, Oxford, 1962)
• [44] V. Desplatetal, Cancer 103, 102 (2005) http://dx.doi.org/10.1002/cncr.20758[Crossref]
• [45] F. Bellocetal, Cancer Biol. Ther. 6, 912 (2007) http://dx.doi.org/10.4161/cbt.6.6.4101[Crossref]
• [46] A. L. Jackson, L. A. Loeb, Genetics 148, 1483 (1998)
• [47] L. A. Loeb, J. M. Essigmann, F. Kazazi et al, Proc. Natl. Acad. Sci. USA 99, 16226 (2002) http://dx.doi.org/10.1073/pnas.202617399[Crossref]
• [48] S. Soverini et al, Clin Cancer Res. 12, 7374 (2006) http://dx.doi.org/10.1158/1078-0432.CCR-06-1516[Crossref]

Identyfikatory

DOI

10.2478/s11534-009-0020-1